EBNEO Commentary: Safety and efficacy of erythropoietin in neonates with hypoxic-ischaemic encephalopathy
- PMID: 36748724
- DOI: 10.1111/apa.16683
EBNEO Commentary: Safety and efficacy of erythropoietin in neonates with hypoxic-ischaemic encephalopathy
Comment on
-
Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.N Engl J Med. 2022 Jul 14;387(2):148-159. doi: 10.1056/NEJMoa2119660. N Engl J Med. 2022. PMID: 35830641 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Oorschot DE, Sizemore RJ, Amer AR. Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: history, current status, and future research. Int J Mol Sci. 2020;21(4):1487.
-
- Razak A, Hussain A. Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. J Perinat Med. 2019;47(4):478-489.
-
- Perrone S, Lembo C, Gironi F, et al. Erythropoietin as a neuroprotective drug for newborn infants: ten years after the first use. Antioxidants (Basel). 2022;11(4):652.
-
- Saad K, Badr-El Din M, Abougabal ASH, Abdel-Salam H. Effect of erythropoietin as adjunctive therapy with whole-body cooling for treatment of hypoxic-ischemic encephalopathy in newborns. Alex J Pediatr. 2017;30(2):45-52.
-
- Wassink G, Davidson JO, Crisostomo A, et al. Recombinant erythropoietin does not augment hypothermic white matter protection after global cerebral ischaemia in near-term fetal sheep. Brain Commun. 2021;3(3):fcab172.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
